Experimental drugs in clinical trials for COPD: Artificial Intelligence via Machine Learning approach to predict the successful advance from early-stage development to approval.

Luigino CalzettaElena PistocchiniAlfredo ChettaRogliani PaolaMario Cazzola

Published in: Expert opinion on investigational drugs (2023)

-adrenoceptor agonists (MABA) navafenterol and batefenterol, the inhaled corticosteroid (ICS)/MABA fluticasone furoate/batefenterol, and the bifunctional phosphodiesterase (PDE) 3/4 inhibitor ensifentrine resulted to have a moderate to very high probability of being approved in the next future, however not before 2025.

Keyphrases

artificial intelligence
machine learning
early stage
clinical trial
drug administration
big data
deep learning
chronic obstructive pulmonary disease
lung function
cystic fibrosis
current status
high intensity
highly efficient
open label
metal organic framework
lymph node